Altimmune
ALT
176 hedge funds and large institutions have $191M invested in Altimmune in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 52 reducing their positions, and 29 closing their positions.
31% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $10.3M
4% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 52
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 182 → 176 (-6)
7.34% less ownership
Funds ownership: 56.91% → 49.57% (-7.3%)
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
35% less capital invested
Capital invested by funds: $292M → $191M (-$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$6.99M |
| 2 |
Millennium Management
New York
|
+$4.85M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.64M |
| 4 |
Two Sigma Investments
New York
|
+$3.44M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$24.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.28M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$3.28M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.59M |
| 5 |
Morgan Stanley
New York
|
-$1.68M |
ALT Hedge Fund Activity: Q1 2025 in Review
176 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2025, worth a combined $191M — down 35% from $292M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ALT and 26 opened new positions — a net loss of 3 holders — while 52 trimmed existing stakes and 54 added.
The largest buyer was Marshall Wace, adding an estimated $6.99M. The largest seller was Ameriprise, cutting an estimated $24.1M.
- 176 institutional investors held Altimmune (ALT) as of Q1 2025, down from 182 in Q4 2024.
- Funds reported $191M of Altimmune stock for Q1 2025, down 35% quarter-over-quarter.
- 26 funds opened new Altimmune positions in Q1 2025 and 29 closed out, a net change of -3 holders.
- The largest Altimmune buyer in Q1 2025 was Marshall Wace, an estimated $6.99M added.
- The largest Altimmune seller in Q1 2025 was Ameriprise, an estimated $24.1M sold.
Based on aggregated 13F filings for Q1 2025.